All three tenses have at least two readings, so the archetype blend applies as printed.
All nine metrics read as filed from the record.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2020-01-29.
From the record
CONMED Corporation's filings since 2017 show 1 warning event: a notice about its exchange listing (8-K item 3.01, the latest 2020-01-29) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+6.8% a year over 10 filed years; profitable in 9 of 10.
From the record
CONMED Corporation's 10 filed years say what it did: revenue went from $764 million in fiscal 2016 to $1.4 billion in fiscal 2025, up 6.8% a year; it rose in 8 of 9 years; the deepest fall was 10% from fiscal 2019 to fiscal 2020; net income was positive in 9 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
Share count grew 1.2% a year. 16% of cash flow returned. Insiders: 1 sales, 0 purchases.
From the record
Over the 3 fiscal years to 2025-12-31, CONMED Corporation's diluted share count grew about 1.2% a year, and dividends and buybacks returned about 16% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 1 sale (1 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-06 (their Form 4 filings).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they doing right now?
Is it financially healthy right now?
ROE 5%: 5¢ of profit per shareholder dollar. Leverage 56%: owes 56¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, CONMED Corporation earned about 5 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 32 cents per dollar of everything the company owns. Leverage: it owed about 56 cents per dollar of assets, and net share issuance: its share count was unchanged over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 32% of 24 in its family; net margin 3.4%.
From the record
CONMED Corporation's standing among 24 graded names in its industry family: revenue of $1.4 billion in fiscal 2025 ranks in the top 15% by size; a net margin of 3.4% ranks in the top 23%; revenue growth of 9.6% a year over the last 3 filed years ranks in the bottom 42% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 35% of 19 in its family for leadership; chief executive since 2025.
From the record
CONMED Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Beyer, Pat (President & CEO, as filed), filing under that title since 2025-01-06, 1.9 years (bottom 36% of its family); the 20 officers and directors filing in the last fifteen months have been on the record a median of 2.9 years (bottom 32%); 14 officer or director changes were reported on Form 8-K since 2023-11-13, against the 20 people in charge now (bottom 38%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 35% of 23 in its family for room to expand.
From the record
CONMED Corporation's room to grow, from the newest filed statements (fiscal 2025): cash of $41 million against debt of $834 million leaves -34.1% of its assets as net cash, bottom 6% of its family; cash from operations less capital spending is 11% of revenue (top 28%); a gross margin of 54.6% (bottom 41%); research spending of 4.1% of revenue (bottom 20%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 46% of 25 in its family for growth drivers.
From the record
CONMED Corporation's growth drivers, from the filed years to fiscal 2025: revenue grew 9.6% a year over the last three filed years against 6.8% over all 10, speeding up (top 28% of its family); the newest year grew 5.2% (bottom 20%); research spending grew 5.8% a year (top 50%); capital spending grew -3.1% a year (bottom 44%) (its annual reports). CONMED Corporation tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 45% of 20 in its family for expectations against reality.
From the record
CONMED Corporation's newest year against its own record: revenue of $1.4 billion in fiscal 2025 came in 5.9% below the $1.5 billion its prior three years' pace pointed to (bottom 31% of its family); net income of $47 million against a prior three-year average of $39 million (top 34%); a net margin of 3.4% against 2.5% before (bottom 38%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made